175 related articles for article (PubMed ID: 34941672)
1. New Modified Recombinant Botulinum Neurotoxin Type F with Enhanced Potency.
Burgin D; Périer C; Hackett G; Elliott M; Kwan D; Hornby F; Mir I; Maignel J; Liu SM; Beard M
Toxins (Basel); 2021 Nov; 13(12):. PubMed ID: 34941672
[TBL] [Abstract][Full Text] [Related]
2. Purification and Characterization of Recombinant Botulinum Neurotoxin Serotype FA, Also Known as Serotype H.
Hackett G; Moore K; Burgin D; Hornby F; Gray B; Elliott M; Mir I; Beard M
Toxins (Basel); 2018 May; 10(5):. PubMed ID: 29751611
[TBL] [Abstract][Full Text] [Related]
3. A comparison of biological activity of commercially available purified native botulinum neurotoxin serotypes A1 to F1 in vitro, ex vivo, and in vivo.
Donald S; Elliott M; Gray B; Hornby F; Lewandowska A; Marlin S; Favre-Guilmard C; Périer C; Cornet S; Kalinichev M; Krupp J; Fonfria E
Pharmacol Res Perspect; 2018 Dec; 6(6):e00446. PubMed ID: 30519475
[TBL] [Abstract][Full Text] [Related]
4. Exchange of the H(CC) domain mediating double receptor recognition improves the pharmacodynamic properties of botulinum neurotoxin.
Rummel A; Mahrhold S; Bigalke H; Binz T
FEBS J; 2011 Dec; 278(23):4506-15. PubMed ID: 21624052
[TBL] [Abstract][Full Text] [Related]
5. Expression and biochemical characterization of light chains of Botulinum neurotoxin subtypes F5 and F7.
Guo J; Chen S
Protein Expr Purif; 2015 Jul; 111():87-90. PubMed ID: 25858313
[TBL] [Abstract][Full Text] [Related]
6. The Light Chain Defines the Duration of Action of Botulinum Toxin Serotype A Subtypes.
Pellett S; Bradshaw M; Tepp WH; Pier CL; Whitemarsh RCM; Chen C; Barbieri JT; Johnson EA
mBio; 2018 Mar; 9(2):. PubMed ID: 29588398
[TBL] [Abstract][Full Text] [Related]
7. Substrate cleavage and duration of action of botulinum neurotoxin type FA ("H, HA").
Pellett S; Tepp WH; Lin G; Johnson EA
Toxicon; 2018 Jun; 147():38-46. PubMed ID: 29273248
[TBL] [Abstract][Full Text] [Related]
8. Botulinum Neurotoxin F Subtypes Cleaving the VAMP-2 Q
Sikorra S; Skiba M; Dorner MB; Weisemann J; Weil M; Valdezate S; Davletov B; Rummel A; Dorner BG; Binz T
Toxins (Basel); 2018 Aug; 10(8):. PubMed ID: 30071628
[TBL] [Abstract][Full Text] [Related]
9. Comparative characterization of botulinum neurotoxin subtypes F1 and F7 featuring differential substrate recognition and cleavage mechanisms.
Guo J; Chan EW; Chen S
Toxicon; 2016 Mar; 111():77-85. PubMed ID: 26748154
[TBL] [Abstract][Full Text] [Related]
10. Generation and Characterization of Six Recombinant Botulinum Neurotoxins as Reference Material to Serve in an International Proficiency Test.
Weisemann J; Krez N; Fiebig U; Worbs S; Skiba M; Endermann T; Dorner MB; Bergström T; Muñoz A; Zegers I; Müller C; Jenkinson SP; Avondet MA; Delbrassinne L; Denayer S; Zeleny R; Schimmel H; Åstot C; Dorner BG; Rummel A
Toxins (Basel); 2015 Nov; 7(12):5035-54. PubMed ID: 26703728
[TBL] [Abstract][Full Text] [Related]
11. Augmentation of VAMP-catalytic activity of botulinum neurotoxin serotype B does not result in increased potency in physiological systems.
Elliott M; Maignel J; Liu SM; Favre-Guilmard C; Mir I; Farrow P; Hornby F; Marlin S; Palan S; Beard M; Krupp J
PLoS One; 2017; 12(10):e0185628. PubMed ID: 28982136
[TBL] [Abstract][Full Text] [Related]
12. Purification and Characterization of Botulinum Neurotoxin FA from a Genetically Modified Clostridium botulinum Strain.
Pellett S; Tepp WH; Bradshaw M; Kalb SR; Dykes JK; Lin G; Nawrocki EM; Pier CL; Barr JR; Maslanka SE; Johnson EA
mSphere; 2016; 1(1):. PubMed ID: 27303710
[TBL] [Abstract][Full Text] [Related]
13. Botulinum neurotoxin X lacks potency in mice and in human neurons.
Gregg BM; Matsumura T; Wentz TG; Tepp WH; Bradshaw M; Stenmark P; Johnson EA; Fujinaga Y; Pellett S
mBio; 2024 Mar; 15(3):e0310623. PubMed ID: 38347673
[TBL] [Abstract][Full Text] [Related]
14. In-Vivo Neutralization of Botulinum Neurotoxin Serotype E Using Rabbit Polyclonal Antibody Developed against BoNT/E Light Chain.
Rani S; Ponmariappan S; Sharma A; Kamboj DV; Jain AK
Protein Pept Lett; 2017; 24(6):495-502. PubMed ID: 28260503
[TBL] [Abstract][Full Text] [Related]
15. Longer-acting and highly potent chimaeric inhibitors of excessive exocytosis created with domains from botulinum neurotoxin A and B.
Wang J; Zurawski TH; Bodeker MO; Meng J; Boddul S; Aoki KR; Dolly JO
Biochem J; 2012 May; 444(1):59-67. PubMed ID: 22360156
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a membrane binding loop leads to engineering botulinum neurotoxin B with improved therapeutic efficacy.
Yin L; Masuyer G; Zhang S; Zhang J; Miyashita SI; Burgin D; Lovelock L; Coker SF; Fu TM; Stenmark P; Dong M
PLoS Biol; 2020 Mar; 18(3):e3000618. PubMed ID: 32182233
[TBL] [Abstract][Full Text] [Related]
17. Recombinant Botulinum Neurotoxin Hc Subunit (BoNT Hc) and Catalytically Inactive Clostridium botulinum Holoproteins (ciBoNT HPs) as Vaccine Candidates for the Prevention of Botulism.
Webb RP; Smith TJ; Smith LA; Wright PM; Guernieri RL; Brown JL; Skerry JC
Toxins (Basel); 2017 Sep; 9(9):. PubMed ID: 28869522
[TBL] [Abstract][Full Text] [Related]
18. Sequence diversity of genes encoding botulinum neurotoxin type F.
Raphael BH; Choudoir MJ; Lúquez C; Fernández R; Maslanka SE
Appl Environ Microbiol; 2010 Jul; 76(14):4805-12. PubMed ID: 20511432
[TBL] [Abstract][Full Text] [Related]
19. Clostridium botulinum neurotoxins act with a wide range of potencies on SH-SY5Y human neuroblastoma cells.
Purkiss JR; Friis LM; Doward S; Quinn CP
Neurotoxicology; 2001 Aug; 22(4):447-53. PubMed ID: 11577803
[TBL] [Abstract][Full Text] [Related]
20. Isolation and Characterization of the Novel Botulinum Neurotoxin A Subtype 6.
Moritz MS; Tepp WH; Bradshaw M; Johnson EA; Pellett S
mSphere; 2018 Oct; 3(5):. PubMed ID: 30355669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
